Inflammation-based score in pediatric adrenocortical carcinoma
Endocrine-Related Cancer · 2025
DOI: 10.1530/erc-24-0244 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Endocrine-Related Cancer, 2025. Verfasst von Maria Riedmeier und 28 weiteren Autor:innen. Hauptthemen laut MEDLINE: Adrenocortical Carcinoma, Adrenal Cortex Neoplasms, Inflammation. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Interdisziplinäres Zentrum für Klinische Forschung, Universitätsklinikum Würzburg, Deutsche Forschungsgemeinschaft.
Abstract (Originalsprache)
Inflammation-based scores have been demonstrated to be independent prognostic factors in predicting outcomes in adult adrenocortical carcinoma (ACC). We aimed to investigate the prognostic role of these scores in pediatric adrenocortical carcinoma (pACC) patients. An international multicenter analysis was conducted on a pediatric cohort from 21 ACC centers. Pretreatment inflammation-based scoring parameters, including neutrophil-to-lymphocyte ratio (NLR), derived neutrophil-to-lymphocyte ratio (dNLR), platelet-to-lymphocyte ratio (PLR), monocyte-to-lymphocyte ratio (MLR) and serum albumin, as well as clinical parameters, were analyzed. The primary endpoint was 10-year overall survival (OS). One hundred twenty-nine pediatric patients (50.4% females, mean age 87 months) across all tumor stages with a median follow-up of 36 months were included. 107/108 patients underwent primary surgery, and 62/106 received systemic treatment at the time of diagnosis. Of 102 patients, 27 died from disease. In the univariable analysis, NLR ≥5 (HR 8.0, 95% CI 3.4–19.1), MLR ≥0.28 (HR 4.2, 95% CI 1.7–10.4), PLR ≥190 (HR 4.5, 95% CI 2.0–10.4) and dNLR ≥1.44 (HR 5.9, 95% CI 2.3–15.5), as well as clinical parameters age ≥4 years (HR 5.5, 95% CI 1.9–15.8), tumor stage IV (HR 5.7, 95% CI 2.7–11.9) and incomplete resection status (HR 8.0, 95% CI 3.6–17.7) were significantly associated with reduced 10-year OS. After multivariable adjustment, only tumor stage IV (HR 336.7, 95% CI 5.8–19,518.1) and MLR ≥0.28 (HR 247.1, 95% CI = 3.1–19,907.5) were significantly associated with an unfavorable outcome. Inflammation-based scores tend to have prognostic value in pACC and could serve as prognostic tools after further validation in future studies with sufficient case numbers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
ORCID-Profile: Maria Riedmeier, Jan Idkowiak, Sonir R R Antonini, Jaydira Del Rivero, Verena Wiegering
Förderung
- Interdisziplinäres Zentrum für Klinische Forschung, Universitätsklinikum Würzburg
- Deutsche Forschungsgemeinschaft
Zitieren
APA
Riedmeier, M., Idkowiak, J., Frey, H., Antonini, S. R. R., Canali, G. F. L., Classen, C. F., Domínguez-Pinilla, N., Fassnacht, M., Fuchs, S., Härtel, C., Janús, D., de Krijger, R., Kutluk, T., Bui, N. L., Meena, J. P., Mezoued, M., Munarin, J., van Noesel, M. M., Köse, N. Ö., …, & Wiegering, V. (2025). Inflammation-based score in pediatric adrenocortical carcinoma. Endocrine-Related Cancer. https://doi.org/10.1530/erc-24-0244
Vancouver
Riedmeier M, Idkowiak J, Frey H, Antonini SRR, Canali GFL, Classen CF, et al. Inflammation-based score in pediatric adrenocortical carcinoma. Endocrine-Related Cancer. 2025. doi:10.1530/erc-24-0244
BibTeX
@article{Riedmeier2025,
author = {Riedmeier, Maria and Idkowiak, Jan and Frey, Heidi and Antonini, Sonir R R and Canali, Gabriela Fernandes Luiz and Classen, Carl Friedrich and Domínguez-Pinilla, Nerea and Fassnacht, Martin and Fuchs, Steffen and Härtel, Christoph and Janús, Dominika and de Krijger, Ronald and Kutluk, Tezer and Bui, Ngoc Lan and Meena, Jagdish Prasad and Mezoued, Mouna and Munarin, Jessica and van Noesel, Max M and Köse, Nihal Özdemir and Pearce, Simon H and Perwein, Thomas and Puglisi, Soraya and Del Rivero, Jaydira and Schlegel, Paul G and Schmid, Irene and Tuli, Gerdi and Walenciak, Justyna and Yalcin, Bilgehan and Wiegering, Verena},
title = {Inflammation-based score in pediatric adrenocortical carcinoma},
journal = {Endocrine-Related Cancer},
year = {2025},
doi = {10.1530/erc-24-0244}
}
EUVIMED